Potential bias associated with modeling the effectiveness of treatment using an overall hazard ratio by Alarid-Escudero, Fernando
Potential bias associated with modeling the effectiveness of treatment using
an overall hazard ratio
Fernando Alarid-Escudero, MSc, Karen M. Kuntz, ScD
Division of Health Policy & Management, School of Public Health, University of Minnesota
Treatment’s efficacy in clinical trials
I Clinical trials often report treatment efficacy in terms of the
reduction of all-cause mortality rate between the treatment
and control arms, i.e., an overall hazard ratio (OHR)
OHRClinical Trial =
µˆTreatment
µˆControl
instead of the specific reduction over the excess hazard from
the disease, i.e., the disease-specific hazard ratio
(DSHR)
I OHR from clinical trials is usually reported over a relatively
short period compared to a life span.
Modeling treatment’s effectiveness
I Decision-analytic models are used to evaluate the
treatment’s effectiveness beyond the trial’s time horizon.
I If we assume the relationship between disease-specific
mortality rate µDis and age-,sex-, and race- specific mortality
rate µASR is additive (i.e., µASR +µDis) and that µASR
doesn’t vary by treatment arm, OHR is defined as
OHR =
µˆASR + µˆ∗Dis
µˆASR + µˆDis
(1)
where µˆASR =
∑Tt=1µASR(t)
T and µˆDis =
∑Tt=1µDis(t)
T , i.e., the
mean rates over the number of periods of the trial T . µˆ∗Dis is
the mean specific mortality rate after the effectiveness of
treatment
µˆ∗Dis = µˆDis ·DSHR (2)
Objective
To quantify the bias associated with using OHR as a
treatment’s efficacy beyond the time horizon of the clinical
trial.
Model
I We simulated a hypothetical cohort of patients with a
generic disease that increases µASR by a constant µDis.
I We compared the effectiveness of treatment under two
approaches
. OHR:
(µASR +µDis) ·OHR
. DSHR:
µASR +µDis ·DSHR
Parameters
Parameter Base case scenario Interval
Age of cohort (yrs.) 50 40-70
µASR
(Annual)
2009 US life tables -
µDis 0.05 0.01-0.09
DSHR 0.5 0.3-0.9
Quantification of bias
We quantified the bias as the percentage change in the life
expectancy (LE) gains (∆LE with treatment vs. no treatment)
under an OHR approach compared to a DSHR approach
Bias =
∆LEOHR−∆LEDSHR
∆LEDSHR
Base Case
For the base-case scenario we assumed a DSHR of 0.5, a 50 year
old cohort and calculated an OHR of 0.54.
Base Case: Mortality rates over time
Mortality rates for base-case scenario
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Healthy: (µASR)
Dis no Rx: (µASR + µDis)
Dis with DSHR Rx: (µASR + µDis ⋅ DSHR)
Dis with OHR Rx: (µASR + µDis) ⋅ OHR
Under OHR approach, at age 81 the mortality rate of individuals
with disease is lower than it would be if they were healthy.
Base Case: Bias
Bias for base-case scenario
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The bias for the base case scenario is a 8.6% increase in the life
expectancy gain.
Bias as a function of DSHR, µDis and age
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Age 40 Age 50
Age 60 Age 70
0.02
0.04
0.06
0.08
0.02
0.04
0.06
0.08
0.4 0.6 0.8 0.4 0.6 0.8
DSHR
µ D
is
5%
10%
15%
Bias: 
The OHR bias ranges between 0.4%-17.5% increase in the life
expectancy gains.
OHR derived from DSHR, µDis and age
OHR
µDis
DSHR
0.3 0.5 0.7 0.9
0.01 0.41 0.58 0.75 0.92
0.03 0.34 0.53 0.72 0.91
0.05 0.32 0.52 0.71 0.90
0.07 0.32 0.51 0.71 0.90
0.09 0.31 0.51 0.71 0.90
(a) Age 40
µDis
DSHR
0.3 0.5 0.7 0.9
0.01 0.51 0.65 0.79 0.93
0.03 0.39 0.56 0.74 0.91
0.05 0.36 0.54 0.72 0.91
0.07 0.34 0.53 0.72 0.91
0.09 0.33 0.52 0.71 0.90
(b) Age 50
µDis
DSHR
0.3 0.5 0.7 0.9
0.01 0.63 0.74 0.84 0.95
0.03 0.46 0.62 0.77 0.92
0.05 0.41 0.58 0.75 0.92
0.07 0.38 0.56 0.73 0.91
0.09 0.36 0.55 0.73 0.91
(c) Age 60
µDis
DSHR
0.3 0.5 0.7 0.9
0.01 0.77 0.83 0.90 0.97
0.03 0.58 0.70 0.82 0.94
0.05 0.50 0.64 0.79 0.93
0.07 0.46 0.61 0.77 0.92
0.09 0.43 0.59 0.75 0.92
(d) Age 70
Alternative solutions
I Using the trial’s information and life tables for the study
population, calculate DSHR substituting Equation (2) into
Equation (1) and solving for DSHR.
DSHR =
(OHR)[µˆASR + µˆDis]− µˆASR
µˆDis
I Use the OHR as an estimate of DSHR, as the latter is not often
reported. The treatment effecitvenes would then be
µASR + (µDis) ·OHR
This results in a slight shift in the mortality rate compared to the
DSHR approach, yielding an underestimation of the LE gain. For
our base-case scenario this approach yields a bias of −2.8%.
Conclusions
I The use of an OHR approach to model treatment effectiveness
beyond the time horizon of the trial overestimates treatment’s
benefit.
I Under an OHR approach it is possible that sick individuals at some
point will face a lower mortality rate compared with healthy
individuals.
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